CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies

Acute Lymphoblastic Leukemia Clinical Trial

Official title:

Immunotherapy With CD19/22 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02443831
• Other study ID #: UCL 14/0529
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: April 2016
• Est. completion date: December 31, 2036

Study information

• Verified date: May 2024
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the safety, efficacy and duration of response of CD19/22 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in children with high risk, relapsed CD19+ and/ or CD22+ haematological malignancies.

Description:

This is a multi-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product named CD19/22 Chimeric Antigen Receptor (CAR) T-cells (CD19/22 CAR T-cells) in children and young adults (age <24 years) with high risk, relapsed CD19+ and/or CD1922+ haematological malignancies (Acute Lymphoblastic Leukemia and Burkitt's lymphoma). Following informed consent and registration to the trial, patients will undergo an unstimulated leukapheresis for the generation of the CD19/22 CAR T-cells. Patients will receive the CD19/22CAR T-cells following lymphodepleting chemotherapy. The study will evaluate the safety, efficacy and duration of response of the CD19/22 CAR T-cells in children with high risk relapsed CD19+ and or CD22+ malignancies.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 38
• Est. completion date: December 31, 2036
• Est. primary completion date: December 31, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 24 Years

Eligibility

Inclusion Criteria:

1. Children and young adults (age 24 years or younger) with high risk/relapsed CD19+ and / or CD22+ haematological malignancy:

A) Resistant disease (>5% blasts) at end of UKALL 2019 guidelines or equivalent induction B) ALL with persisting high level MRD at 2nd time point of frontline national protocol (currently MRD >10-4 at week 14 UKALL2019 guidelines or equivalent).

C) High risk infant ALL (age < 6 months at diagnosis with MLL gene rearrangement and either presenting white cell count > 300 x 109/L or poor steroid early response (i.e. circulating blast count >1x109/L following 7 day steroid pre-phase of induction as per national guidelines or equivalent) D) Intermediate risk infant ALL with MRD > 10-3 at end of induction following national guidelines or equivalent) E) High risk 1st relapse (as defined by updated IntreALL 2019 classification: bone marrow or combined relapse within 30 months of diagnosis OR any relapse within 18 months of diagnosis) F) Standard risk relapse in patients with high risk cytogenetics (defined as BCR-ABL, KMT2A rearrangement, near-haploidy (<30 chromosomes) and low hypodiploidy (30-39 chromosomes), iAMP21 and TCF3-HLF translocations).

G) Standard risk relapse with bone marrow minimal residual disease (MRD) > 10-3 at end of re-induction H) Any on therapy relapse in patients age 16-24 I) Any relapse of infant ALL J) ALL post = 2nd relapse K) Any refractory relapse of ALL (defined as > 1% blasts by flow cytometry after a at least 1 cycle of standard chemotherapy) L) ALL with MRD >10-4 prior to planned stem cell transplant M) Any relapse of ALL eligible for stem cell transplant but no available HLA matched donor or other contraindication to transplant N) Any relapse of ALL after stem cell transplant O) Any relapse of Burkitt's or other CD19+ and/or CD22+lymphoma Note patients with isolated CNS relapse meeting one or more of the criteria above are eligible for the study

2. Agreement to have a pregnancy test, use adequate contraception (if applicable)

3. Written informed consent

Exclusion Criteria:

• Exclusion Criteria for registration:

1. Active Hepatitis B, C or HIV infection

2. Oxygen saturation = 90% on air

3. Bilirubin > 3 x upper limit of normal

4. Creatinine > 3 x upper limit of normal

5. Women who are pregnant or breastfeeding

6. Stem Cell Transplant patients only: active significant (overall Grade = II, Seattle criteria) acute GVHD or moderate/ severe chronic GVHD (NIH consensus criteria) requiring systemic steroids.

7. Inability to tolerate leucapheresis

8. Karnofsky (age = 10 years) or Lansky (age < 10) score = 50%

9. Pre-existing significant neurological disorder (other than CNS involvement of underlying haematological malignancy)

Exclusion criteria for CD19/22CAR T-cell infusion:

1. Severe intercurrent infection at the time of scheduled CD19/22 CAR T-cell infusion

2. Requirement for supplementary oxygen or active pulmonary infiltrates at the time of scheduled CD19/22 CAR T-cell infusion

3. Allogeneic transplant recipients with active significant acute GVHD overall grade =II or moderate/severe chronic GVHD requiring systemic steroids at the time of scheduled CD19/22 CAR T-cell infusion. Note: Such patients will be excluded until the patient is GVHD free and off steroids

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Burkitt Lymphoma
• Hematologic Neoplasms
• Leukemia
• Leukemia, Lymphoid
• Neoplasms
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Procedure:
• Leukapheresis
Patients will undergo an unstimulated leukapheresis to isolate the required immune cells to produce the CD19/22 CAR T-cells

Drug:
• Lymphodepletion with fludarabine
Patients will receive lymphodepleting chemotherapy with iv fludarabine 30 mg/m2 on days -7 to -3 prior to CD19/22CAR T-cell infusion.
• Lymphodepletion with cyclophosphamide
Patients will receive lymphodepleting chemotherapy with iv cyclophosphamide 0.5 g/m2 on days -4 to -2 prior to CD19/22CAR T-cell infusion.

Biological:
• CD19/22 CAR T-cells
A single dose of 1 x 10^6/kg CD19/22CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.

Locations

Country	Name	City	State
United Kingdom	Great Ormond Street Hospital	London
United Kingdom	University College Hospital	London
United Kingdom	Manchester Royal Children's Hospital	Manchester

Sponsors (1)

Lead Sponsor	Collaborator
University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Toxicity evaluation following CD19/22CAR T-cell infusion	The incidence of grade 3-5 toxicity occurring within 60 days of CD19/22CAR T-cell infusion. In particular, the incidence of Severe Cytokine Release Syndrome and Grade 3-5 neurotoxicity occurring within 30 days of CD19/22CAR T-cell infusion.	1 month
Primary	Molecular remission	Efficacy will be assessed by determining Minimal Residual Disease in the bone marrow aspirate using immunoglobulin heavy chain (IgH) quantitative polymerase chain reaction (qPCR) and/or Next Generation Sequencing in all patients. The proportion of patients achieving molecular remission at 1 month post CD19/22CAR T-cell infusion will be determined.	1 month
Secondary	Long term molecular remission	Number of patients in molecular remission without further therapy at 2 years	2 years
Secondary	Frequency of circulating CD19/22 CAR T-cells	Persistence and frequency of circulating CD19/22CAR T-cells in the peripheral blood by flow cytometry and qPCR analyses.	2 years
Secondary	Incidence of hypogammaglobulinaemia	Incidence and duration of hypogammaglobulinaemia	2 years
Secondary	Relapse rate	Relapse rate monitored during interventional phase and long term follow up for a total of10 years post cell infusion. Number of patients who relapsed can be summarized as a percentage or rate(for all patients registered to the trial, and also only for those who received the cell infusion).	10 years
Secondary	Overall Survival	Overall survival is monitored during interventional phase and long term follow up for 10 years post-CD19/22 CAR T-cell infusion. Number of patients alive can be summarized as a percentage (for all patients registered to the trial, and also only for those who received the cell infusion).	10 years